Probiotix Health

Probiotix Health EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Probiotix Health (PBX.AQ) as of Nov 3, 2026 is -6.56. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -30.10 — a change of -78.20% (higher).

EV/FCF

-6.56

YoY

-78.20%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Probiotix Health is 2024 -6.56 . EV/FCF (Enterprise Value to Free Cash Flow) of Probiotix Health was 2023 -30.10 . It decreases by -78.20% higher compared to the previous year.

The Probiotix Health EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-15.87 GBP
Jan 1, 2020
-231.17 GBP
Jan 1, 2021
1,280.40 GBP
Jan 1, 2022
-8.97 GBP
Jan 1, 2023
-30.10 GBP
Jan 1, 2024
-6.56 GBP
The Probiotix Health EV/FCF history
YEAREV/FCFYoY
-6.56-78.20%
-30.10+235.52%
-8.97-100.70%
1,280.40-653.87%
-231.17+1,356.30%
-15.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Probiotix Health Stock analysis

What does Probiotix Health do? ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets. Probiotix Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Probiotix Health stock

EV/FCF (Enterprise Value to Free Cash Flow) of Probiotix Health is -6.56 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Probiotix Health changed from -30.10 to -6.56, representing a -78.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Probiotix Health since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Probiotix Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Probiotix Health

All Key Metrics — Probiotix Health